Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

ConditionGlioma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRegina Elena Cancer Institute

About this trial

Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.

Eligibility criteria

Qualifiers

histological diagnosis of glioma;

no concomitant primary tumor;

no metastatic disease;

availability of surgical material/tissue;

Disqualifiers

histological diagnosis of non-glial tumor;

patients with concomitant other solid tumors;

metastatic disease;

no surgical material/tissue available;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Regina Elena Cancer Institute

Lead sponsor

University of Roma La Sapienza

Collaborator

San Camillo Hospital, Rome

Collaborator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator

Neuromed IRCCS

Collaborator